Rheumatoide Arthritis: Langzeitkontrolle der DMARD-Therapie besser individualisiert als routinemäßig?

Background: Scarcity of data on the value of long-term routine laboratory toxicity monitoring (lt-RLTM) during disease-modifying antirheumatic drug (DMARD) use results in frequent monitoring in clinical practice. Objective: To determine the cumulative incidence of abnormal and very abnormal laboratory monitoring results among patients with rheumatoid arthritis (RA) and to characterize the clinical context for the incidence of new very abnormal results. Design: Retrospective cohort study. Setting: The Netherlands, July 2008 to April 2020. Patients: Patients with RA undergoing lt-RLTM after at least 6 months of DMARD use. Measure: ments: Cumulative probabilities of abnormal and very abnormal results were calculated for alanine aminotransferase (>100 and >300 U/L), estimated glomerular filtration rate (eGFR;